INOVIO Q1 2023 net loss $40.6M; VGX-3100 misses in biomarker population

INOVIO PHARMACEUTICALS, INC.

2023-Q1 EPS reported -$0.16 revenue$114,943

Net loss $40.6M ($0.16/sh) vs $79.1M ($0.36) in Q1 2022; revenue $115K vs $199K.
Cash and equivalents $223.8M as of March 31; runway projected into Q1 2025.
Phase 3 VGX-3100 for cervical HSIL missed primary endpoint in biomarker population but achieved statistical significance in all-participants.
INO-3107 for RRP: 10 of 11 (91%) patients saw reduction in surgical interventions; well-tolerated.
Appointed Dr. Cheryl Elder as SVP Regulatory Affairs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INOVIO PHARMACEUTICALS, INC. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 10, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

INOVIO PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-140755

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.